SCHEMBL6764639

SCHEMBL6764639

CC(O)(CS(=O)(=O)c1ccc(NC(=O)c2ccccc2)cc1)C(=O)NO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 2/20 0.55
LMNA P02545 3/20 0.53
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
HPGD P15428 2/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP2D6 P10635 1/20 0.50
MMP2 P08253 4/20 0.49
MMP13 P45452 3/20 0.49
MMP1 P03956 2/20 0.49
TRPV4 Q9HBA0 1/20 0.49
MMP9 P14780 1/20 0.49
MAPT P10636 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764641 0.88 MAPT (0.54) PRMT1KMT2AMEN1CA12CA1
SCHEMBL6767619 0.88 CYP2C19 (0.55) LMNAKMT2AMEN1HPGDCA12
SCHEMBL6764633 0.88 NPC1 (0.52) LMNAKMT2AMEN1HPGDCYP3A4
SCHEMBL6768091 0.87 MAPT (0.53) LMNAKMT2AMEN1CYP3A4CYP2C9
SCHEMBL6764893 0.87 PTGS1 (0.50) PRMT1KMT2AMEN1HPGDCYP3A4
SCHEMBL6768704 0.87 CYP2C19 (0.50) KMT2AMEN1HPGDCYP3A4CYP2C9
SCHEMBL6764678 0.85 ENPP1 (0.53) LMNAKMT2AMEN1CA1CA2
SCHEMBL6764878 0.85 TP53 (0.56) LMNAKMT2AMEN1HPGDALDH1A1
SCHEMBL27402220 0.84 PRMT1 (0.48) PRMT1LMNAKMT2AMEN1HPGD
SCHEMBL6768715 0.83 KDM4E (0.57) KMT2AHPGDCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed
EP-0984959-A4 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO CO (US) 2001-05-02 EP disclosed
EP-0984959-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-03-15 EP disclosed
WO-1998039326-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 PRMT1 4132/4885LMNA 1455/4885KMT2A 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.